Concepts (347)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cognition | 49 | 2023 | 1339 | 7.760 |
Why?
|
| Brain | 40 | 2023 | 1648 | 4.870 |
Why?
|
| White Matter | 11 | 2022 | 137 | 4.600 |
Why?
|
| Aging | 36 | 2023 | 1555 | 4.540 |
Why?
|
| Cognitive Dysfunction | 32 | 2023 | 1069 | 3.910 |
Why?
|
| Aged | 118 | 2023 | 9119 | 3.720 |
Why?
|
| Neuropsychological Tests | 61 | 2023 | 1198 | 3.500 |
Why?
|
| Alzheimer Disease | 30 | 2023 | 2119 | 3.470 |
Why?
|
| Cardiovascular Diseases | 13 | 2023 | 324 | 3.330 |
Why?
|
| Magnetic Resonance Imaging | 38 | 2023 | 1108 | 2.870 |
Why?
|
| Cognition Disorders | 19 | 2020 | 986 | 2.820 |
Why?
|
| Diffusion Tensor Imaging | 12 | 2023 | 61 | 2.710 |
Why?
|
| Humans | 147 | 2023 | 27309 | 2.610 |
Why?
|
| Female | 103 | 2023 | 15334 | 2.520 |
Why?
|
| Male | 100 | 2023 | 14887 | 2.480 |
Why?
|
| Hypertension | 7 | 2022 | 194 | 2.380 |
Why?
|
| Depression | 8 | 2020 | 446 | 2.200 |
Why?
|
| Executive Function | 21 | 2023 | 110 | 2.130 |
Why?
|
| Middle Aged | 72 | 2023 | 9068 | 2.080 |
Why?
|
| Blood Pressure | 8 | 2022 | 196 | 1.930 |
Why?
|
| Aged, 80 and over | 55 | 2023 | 4841 | 1.900 |
Why?
|
| Verbal Learning | 11 | 2021 | 33 | 1.770 |
Why?
|
| Dementia | 16 | 2023 | 567 | 1.750 |
Why?
|
| Memory Disorders | 7 | 2018 | 160 | 1.710 |
Why?
|
| Acculturation | 3 | 2023 | 31 | 1.700 |
Why?
|
| Memory, Short-Term | 11 | 2023 | 96 | 1.660 |
Why?
|
| Diet, Mediterranean | 5 | 2023 | 101 | 1.660 |
Why?
|
| Connectome | 5 | 2021 | 13 | 1.650 |
Why?
|
| Risk Factors | 26 | 2023 | 2335 | 1.580 |
Why?
|
| Gray Matter | 5 | 2023 | 51 | 1.530 |
Why?
|
| Prefrontal Cortex | 7 | 2016 | 136 | 1.510 |
Why?
|
| Neuroimaging | 10 | 2023 | 129 | 1.460 |
Why?
|
| Health Literacy | 3 | 2023 | 108 | 1.410 |
Why?
|
| Cerebrovascular Disorders | 4 | 2021 | 132 | 1.340 |
Why?
|
| Residence Characteristics | 4 | 2021 | 216 | 1.280 |
Why?
|
| Decision Making | 6 | 2023 | 220 | 1.250 |
Why?
|
| Brain Mapping | 10 | 2021 | 149 | 1.150 |
Why?
|
| Arteriolosclerosis | 3 | 2023 | 78 | 1.150 |
Why?
|
| Public Health | 6 | 2021 | 71 | 1.140 |
Why?
|
| Mental Status and Dementia Tests | 4 | 2021 | 56 | 1.060 |
Why?
|
| United States | 18 | 2021 | 2078 | 1.060 |
Why?
|
| Depressive Disorder | 5 | 2017 | 175 | 1.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2018 | 164 | 1.020 |
Why?
|
| Cohort Studies | 19 | 2023 | 1903 | 1.010 |
Why?
|
| Depressive Disorder, Major | 9 | 2018 | 99 | 0.990 |
Why?
|
| Nerve Fibers, Myelinated | 5 | 2013 | 27 | 0.990 |
Why?
|
| Tryptophan | 5 | 2014 | 10 | 0.980 |
Why?
|
| Memory | 10 | 2021 | 295 | 0.980 |
Why?
|
| Apolipoproteins E | 4 | 2023 | 253 | 0.960 |
Why?
|
| Exercise | 7 | 2022 | 452 | 0.930 |
Why?
|
| Stroke | 5 | 2023 | 269 | 0.930 |
Why?
|
| Cognitive Aging | 3 | 2020 | 79 | 0.920 |
Why?
|
| Cross-Sectional Studies | 14 | 2023 | 903 | 0.920 |
Why?
|
| Hippocampus | 9 | 2022 | 275 | 0.890 |
Why?
|
| Educational Status | 5 | 2023 | 289 | 0.880 |
Why?
|
| Psychomotor Performance | 9 | 2020 | 204 | 0.870 |
Why?
|
| Pattern Recognition, Visual | 2 | 2019 | 18 | 0.860 |
Why?
|
| Diabetes Mellitus | 3 | 2020 | 130 | 0.850 |
Why?
|
| Linear Models | 6 | 2020 | 247 | 0.830 |
Why?
|
| Spatial Processing | 2 | 2021 | 6 | 0.830 |
Why?
|
| Adult | 28 | 2023 | 7946 | 0.810 |
Why?
|
| Mental Recall | 7 | 2020 | 62 | 0.800 |
Why?
|
| Income | 3 | 2021 | 81 | 0.800 |
Why?
|
| Genotype | 5 | 2020 | 344 | 0.780 |
Why?
|
| Social Participation | 1 | 2022 | 12 | 0.770 |
Why?
|
| Leukoaraiosis | 3 | 2012 | 9 | 0.760 |
Why?
|
| Blood Glucose | 2 | 2022 | 108 | 0.760 |
Why?
|
| Crime Victims | 1 | 2022 | 31 | 0.760 |
Why?
|
| Analysis of Variance | 10 | 2017 | 258 | 0.740 |
Why?
|
| Clinical Protocols | 1 | 2022 | 58 | 0.740 |
Why?
|
| Anisotropy | 5 | 2023 | 44 | 0.740 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 44 | 0.720 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2018 | 165 | 0.720 |
Why?
|
| Longitudinal Studies | 13 | 2023 | 1380 | 0.710 |
Why?
|
| Cerebral Cortex | 4 | 2021 | 154 | 0.710 |
Why?
|
| Psychology | 1 | 2021 | 21 | 0.710 |
Why?
|
| Optimism | 1 | 2021 | 2 | 0.700 |
Why?
|
| Family Relations | 1 | 2021 | 13 | 0.700 |
Why?
|
| Antihypertensive Agents | 2 | 2020 | 54 | 0.690 |
Why?
|
| Social Segregation | 1 | 2020 | 7 | 0.680 |
Why?
|
| Social Environment | 1 | 2021 | 77 | 0.680 |
Why?
|
| Dementia, Vascular | 5 | 2020 | 45 | 0.680 |
Why?
|
| Racism | 1 | 2021 | 33 | 0.680 |
Why?
|
| Cholesterol | 2 | 2019 | 63 | 0.660 |
Why?
|
| Loneliness | 1 | 2021 | 59 | 0.660 |
Why?
|
| Social Capital | 1 | 2020 | 3 | 0.660 |
Why?
|
| Dyslipidemias | 1 | 2019 | 16 | 0.640 |
Why?
|
| Triglycerides | 1 | 2019 | 62 | 0.630 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 39 | 0.630 |
Why?
|
| Social Support | 1 | 2021 | 194 | 0.630 |
Why?
|
| Life Style | 1 | 2021 | 186 | 0.630 |
Why?
|
| Hyperinsulinism | 1 | 2019 | 4 | 0.620 |
Why?
|
| Mental Processes | 1 | 2019 | 17 | 0.610 |
Why?
|
| Cultural Diversity | 1 | 2019 | 22 | 0.610 |
Why?
|
| Prospective Studies | 13 | 2022 | 1792 | 0.600 |
Why?
|
| Community Health Services | 1 | 2019 | 34 | 0.600 |
Why?
|
| Insulin Resistance | 1 | 2019 | 50 | 0.600 |
Why?
|
| Neural Pathways | 9 | 2018 | 63 | 0.600 |
Why?
|
| Stress, Psychological | 1 | 2021 | 235 | 0.590 |
Why?
|
| Multilingualism | 1 | 2019 | 21 | 0.590 |
Why?
|
| Independent Living | 6 | 2022 | 321 | 0.590 |
Why?
|
| Kidney | 1 | 2019 | 152 | 0.590 |
Why?
|
| Phenotype | 2 | 2019 | 313 | 0.580 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2023 | 164 | 0.570 |
Why?
|
| Psychological Trauma | 1 | 2017 | 4 | 0.550 |
Why?
|
| Affect | 3 | 2013 | 60 | 0.530 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 369 | 0.520 |
Why?
|
| Serotonin | 4 | 2014 | 23 | 0.520 |
Why?
|
| Wounds and Injuries | 1 | 2017 | 46 | 0.520 |
Why?
|
| Individuality | 1 | 2016 | 23 | 0.500 |
Why?
|
| Metabolic Diseases | 1 | 2015 | 8 | 0.460 |
Why?
|
| Thinking | 1 | 2014 | 14 | 0.450 |
Why?
|
| Psychomotor Disorders | 1 | 2014 | 10 | 0.450 |
Why?
|
| Verbal Behavior | 5 | 2009 | 16 | 0.450 |
Why?
|
| Obesity | 4 | 2023 | 309 | 0.440 |
Why?
|
| Sex Factors | 6 | 2020 | 469 | 0.440 |
Why?
|
| Age Factors | 8 | 2020 | 779 | 0.430 |
Why?
|
| Surveys and Questionnaires | 10 | 2021 | 1156 | 0.430 |
Why?
|
| Frontal Lobe | 5 | 2018 | 82 | 0.420 |
Why?
|
| Vascular Diseases | 2 | 2013 | 42 | 0.420 |
Why?
|
| Memory, Episodic | 3 | 2018 | 116 | 0.410 |
Why?
|
| Alleles | 5 | 2023 | 208 | 0.410 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2012 | 33 | 0.400 |
Why?
|
| Health Surveys | 4 | 2021 | 88 | 0.390 |
Why?
|
| Attention | 6 | 2023 | 124 | 0.390 |
Why?
|
| Models, Statistical | 3 | 2021 | 127 | 0.380 |
Why?
|
| Galvanic Skin Response | 1 | 2011 | 7 | 0.370 |
Why?
|
| Gambling | 1 | 2011 | 8 | 0.370 |
Why?
|
| Case-Control Studies | 9 | 2023 | 589 | 0.370 |
Why?
|
| Models, Psychological | 1 | 2011 | 68 | 0.360 |
Why?
|
| Dancing | 2 | 2021 | 14 | 0.360 |
Why?
|
| Down Syndrome | 1 | 2011 | 10 | 0.360 |
Why?
|
| Biomarkers | 4 | 2021 | 562 | 0.360 |
Why?
|
| Brain Chemistry | 1 | 2011 | 45 | 0.350 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2023 | 162 | 0.350 |
Why?
|
| Crime | 2 | 2021 | 8 | 0.350 |
Why?
|
| Basal Ganglia Cerebrovascular Disease | 1 | 2010 | 3 | 0.330 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2016 | 197 | 0.330 |
Why?
|
| Sex Characteristics | 2 | 2022 | 118 | 0.330 |
Why?
|
| Chicago | 3 | 2021 | 953 | 0.320 |
Why?
|
| Reaction Time | 6 | 2023 | 102 | 0.320 |
Why?
|
| Neural Inhibition | 2 | 2014 | 8 | 0.310 |
Why?
|
| Apolipoprotein E4 | 3 | 2020 | 265 | 0.290 |
Why?
|
| Psychiatric Status Rating Scales | 7 | 2017 | 309 | 0.290 |
Why?
|
| Myelin Sheath | 2 | 2021 | 26 | 0.280 |
Why?
|
| Amnesia | 5 | 2020 | 24 | 0.280 |
Why?
|
| Learning | 2 | 2018 | 72 | 0.270 |
Why?
|
| Self Report | 3 | 2023 | 225 | 0.270 |
Why?
|
| Hospitalization | 2 | 2019 | 315 | 0.260 |
Why?
|
| Visual Perception | 2 | 2020 | 29 | 0.260 |
Why?
|
| Principal Component Analysis | 3 | 2021 | 23 | 0.260 |
Why?
|
| Language | 3 | 2021 | 63 | 0.260 |
Why?
|
| Reproducibility of Results | 4 | 2021 | 675 | 0.260 |
Why?
|
| Young Adult | 7 | 2021 | 2032 | 0.260 |
Why?
|
| Nerve Net | 5 | 2018 | 40 | 0.250 |
Why?
|
| Prevalence | 4 | 2021 | 458 | 0.250 |
Why?
|
| Pilot Projects | 3 | 2022 | 415 | 0.250 |
Why?
|
| DNA-Binding Proteins | 3 | 2023 | 275 | 0.240 |
Why?
|
| Problem Solving | 2 | 2009 | 41 | 0.230 |
Why?
|
| Discrimination Learning | 1 | 2004 | 1 | 0.220 |
Why?
|
| Color Perception | 1 | 2004 | 5 | 0.220 |
Why?
|
| Severity of Illness Index | 5 | 2017 | 893 | 0.220 |
Why?
|
| Temporal Lobe | 3 | 2018 | 90 | 0.220 |
Why?
|
| Models, Neurological | 3 | 2018 | 27 | 0.220 |
Why?
|
| Arousal | 1 | 2004 | 50 | 0.220 |
Why?
|
| Time Factors | 2 | 2019 | 1444 | 0.200 |
Why?
|
| Autistic Disorder | 2 | 2014 | 40 | 0.200 |
Why?
|
| Postmenopause | 1 | 2023 | 57 | 0.200 |
Why?
|
| Adolescent | 6 | 2021 | 2185 | 0.200 |
Why?
|
| Research Design | 2 | 2021 | 189 | 0.200 |
Why?
|
| Intelligence Tests | 2 | 2015 | 16 | 0.200 |
Why?
|
| Fraud | 1 | 2022 | 21 | 0.190 |
Why?
|
| Psychometrics | 2 | 2021 | 218 | 0.190 |
Why?
|
| Atherosclerosis | 1 | 2023 | 55 | 0.190 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 486 | 0.190 |
Why?
|
| Socioeconomic Factors | 2 | 2021 | 305 | 0.190 |
Why?
|
| HIV Infections | 2 | 2021 | 477 | 0.190 |
Why?
|
| Geriatric Assessment | 3 | 2017 | 209 | 0.190 |
Why?
|
| Regression Analysis | 5 | 2018 | 258 | 0.190 |
Why?
|
| Awareness | 1 | 2002 | 42 | 0.180 |
Why?
|
| Facial Expression | 2 | 2012 | 8 | 0.180 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2023 | 114 | 0.180 |
Why?
|
| Data Interpretation, Statistical | 3 | 2022 | 76 | 0.180 |
Why?
|
| Genome-Wide Association Study | 2 | 2020 | 276 | 0.180 |
Why?
|
| Emotions | 2 | 2012 | 72 | 0.180 |
Why?
|
| Social Identification | 1 | 2021 | 8 | 0.180 |
Why?
|
| Social Networking | 1 | 2021 | 11 | 0.180 |
Why?
|
| Accelerometry | 2 | 2021 | 89 | 0.180 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2021 | 13 | 0.170 |
Why?
|
| Treatment Outcome | 2 | 2022 | 3540 | 0.170 |
Why?
|
| Southeastern United States | 1 | 2020 | 14 | 0.170 |
Why?
|
| Midwestern United States | 1 | 2020 | 50 | 0.170 |
Why?
|
| Organ Size | 3 | 2023 | 95 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 291 | 0.170 |
Why?
|
| Mental Status Schedule | 3 | 2011 | 90 | 0.170 |
Why?
|
| Wechsler Scales | 3 | 2006 | 11 | 0.170 |
Why?
|
| Space Perception | 1 | 2020 | 22 | 0.160 |
Why?
|
| Acute Disease | 2 | 2012 | 180 | 0.160 |
Why?
|
| Judgment | 1 | 2019 | 6 | 0.160 |
Why?
|
| Cholesterol, HDL | 1 | 2019 | 26 | 0.160 |
Why?
|
| Disabled Persons | 1 | 2021 | 122 | 0.160 |
Why?
|
| Cholesterol, LDL | 1 | 2019 | 29 | 0.160 |
Why?
|
| Patient Selection | 1 | 2021 | 197 | 0.160 |
Why?
|
| Pandemics | 1 | 2021 | 243 | 0.160 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 331 | 0.160 |
Why?
|
| Interpersonal Relations | 1 | 2020 | 101 | 0.160 |
Why?
|
| Hypercholesterolemia | 1 | 2019 | 23 | 0.150 |
Why?
|
| Atrophy | 2 | 2016 | 87 | 0.150 |
Why?
|
| Financing, Personal | 1 | 2018 | 22 | 0.150 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 1807 | 0.150 |
Why?
|
| Emergencies | 1 | 2019 | 32 | 0.150 |
Why?
|
| Energy Intake | 1 | 2019 | 83 | 0.150 |
Why?
|
| Cognitive Reserve | 1 | 2019 | 39 | 0.150 |
Why?
|
| Genetic Variation | 1 | 2018 | 97 | 0.150 |
Why?
|
| Heterozygote | 1 | 2018 | 102 | 0.140 |
Why?
|
| Double-Blind Method | 3 | 2014 | 408 | 0.140 |
Why?
|
| Healthy Aging | 1 | 2017 | 15 | 0.130 |
Why?
|
| Healthy Lifestyle | 1 | 2017 | 45 | 0.130 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2016 | 17 | 0.130 |
Why?
|
| Phobia, Social | 1 | 2016 | 13 | 0.130 |
Why?
|
| Parkinson Disease | 2 | 2020 | 671 | 0.130 |
Why?
|
| Motor Skills | 1 | 2017 | 48 | 0.130 |
Why?
|
| Predictive Value of Tests | 2 | 2011 | 478 | 0.130 |
Why?
|
| Neurodegenerative Diseases | 1 | 2018 | 125 | 0.130 |
Why?
|
| Self-Assessment | 2 | 2020 | 29 | 0.130 |
Why?
|
| Prognosis | 1 | 2019 | 808 | 0.130 |
Why?
|
| Gyrus Cinguli | 2 | 2016 | 14 | 0.130 |
Why?
|
| Anxiety Disorders | 1 | 2017 | 170 | 0.120 |
Why?
|
| Bipolar Disorder | 1 | 2016 | 107 | 0.120 |
Why?
|
| Urban Population | 1 | 2017 | 154 | 0.120 |
Why?
|
| Cytokines | 1 | 2017 | 238 | 0.120 |
Why?
|
| Cerebrovascular Circulation | 2 | 2014 | 33 | 0.110 |
Why?
|
| Inflammation | 3 | 2023 | 287 | 0.110 |
Why?
|
| Macromolecular Substances | 1 | 2014 | 6 | 0.110 |
Why?
|
| Statistics as Topic | 1 | 2014 | 103 | 0.110 |
Why?
|
| Animals | 2 | 2013 | 3682 | 0.110 |
Why?
|
| Axons | 1 | 2013 | 28 | 0.110 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2016 | 231 | 0.100 |
Why?
|
| Oxygen | 1 | 2012 | 66 | 0.100 |
Why?
|
| Visual Cortex | 1 | 2012 | 6 | 0.100 |
Why?
|
| Auditory Cortex | 1 | 2012 | 3 | 0.100 |
Why?
|
| Language Tests | 2 | 2021 | 33 | 0.090 |
Why?
|
| Photic Stimulation | 3 | 2020 | 26 | 0.090 |
Why?
|
| Reward | 1 | 2011 | 23 | 0.090 |
Why?
|
| Task Performance and Analysis | 1 | 2011 | 47 | 0.090 |
Why?
|
| Social Class | 2 | 2022 | 64 | 0.090 |
Why?
|
| Inositol | 1 | 2011 | 6 | 0.090 |
Why?
|
| Aspartic Acid | 1 | 2011 | 13 | 0.090 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2011 | 37 | 0.090 |
Why?
|
| Genes, MHC Class I | 1 | 2010 | 4 | 0.090 |
Why?
|
| HLA-B Antigens | 1 | 2010 | 8 | 0.090 |
Why?
|
| Antigen Presentation | 1 | 2010 | 16 | 0.090 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 606 | 0.090 |
Why?
|
| Syndrome | 1 | 2010 | 73 | 0.080 |
Why?
|
| Weight Loss | 2 | 2023 | 127 | 0.080 |
Why?
|
| Pain Measurement | 1 | 2011 | 486 | 0.080 |
Why?
|
| Medicare | 2 | 2019 | 123 | 0.070 |
Why?
|
| Cues | 2 | 2011 | 38 | 0.070 |
Why?
|
| HIV-1 | 1 | 2010 | 235 | 0.070 |
Why?
|
| Neuropathology | 2 | 2019 | 82 | 0.070 |
Why?
|
| Comorbidity | 1 | 2009 | 488 | 0.070 |
Why?
|
| Adaptation, Physiological | 1 | 2007 | 47 | 0.070 |
Why?
|
| Cluster Analysis | 2 | 2011 | 47 | 0.070 |
Why?
|
| Functional Laterality | 1 | 2007 | 62 | 0.070 |
Why?
|
| Lewy Bodies | 2 | 2019 | 193 | 0.070 |
Why?
|
| Reading | 1 | 2006 | 38 | 0.060 |
Why?
|
| Evoked Potentials | 1 | 2004 | 13 | 0.060 |
Why?
|
| Dominance, Cerebral | 1 | 2004 | 16 | 0.060 |
Why?
|
| Limbic System | 1 | 2004 | 7 | 0.060 |
Why?
|
| Disease Progression | 2 | 2021 | 672 | 0.050 |
Why?
|
| Cross-Over Studies | 2 | 2014 | 67 | 0.050 |
Why?
|
| Reproduction | 1 | 2023 | 10 | 0.050 |
Why?
|
| Estrogens | 1 | 2023 | 26 | 0.050 |
Why?
|
| Baltimore | 1 | 2003 | 10 | 0.050 |
Why?
|
| Sample Size | 1 | 2003 | 18 | 0.050 |
Why?
|
| Age of Onset | 2 | 2013 | 95 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 57 | 0.050 |
Why?
|
| Infarction | 1 | 2023 | 29 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2023 | 33 | 0.050 |
Why?
|
| Reference Values | 1 | 2003 | 185 | 0.050 |
Why?
|
| Maze Learning | 1 | 2002 | 16 | 0.050 |
Why?
|
| Pregnancy | 1 | 2023 | 339 | 0.050 |
Why?
|
| Boston | 1 | 2022 | 21 | 0.050 |
Why?
|
| Physical Therapy Modalities | 1 | 2022 | 74 | 0.050 |
Why?
|
| Cholinergic Antagonists | 1 | 2022 | 10 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 147 | 0.050 |
Why?
|
| Psychotic Disorders | 1 | 2002 | 36 | 0.050 |
Why?
|
| Incidental Findings | 1 | 2021 | 14 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 35 | 0.050 |
Why?
|
| Probability | 1 | 2021 | 88 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2021 | 55 | 0.040 |
Why?
|
| Caribbean Region | 1 | 2020 | 3 | 0.040 |
Why?
|
| South America | 1 | 2020 | 3 | 0.040 |
Why?
|
| Information Dissemination | 1 | 2021 | 19 | 0.040 |
Why?
|
| Amino Acids | 2 | 2010 | 20 | 0.040 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2020 | 5 | 0.040 |
Why?
|
| Lung | 1 | 2021 | 169 | 0.040 |
Why?
|
| New York | 1 | 2020 | 11 | 0.040 |
Why?
|
| Florida | 1 | 2020 | 17 | 0.040 |
Why?
|
| California | 1 | 2020 | 36 | 0.040 |
Why?
|
| Orientation | 1 | 2020 | 5 | 0.040 |
Why?
|
| Walking | 1 | 2022 | 253 | 0.040 |
Why?
|
| Puerto Rico | 1 | 2019 | 12 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2020 | 57 | 0.040 |
Why?
|
| Cerebral Ventricles | 1 | 2019 | 19 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2019 | 29 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 350 | 0.040 |
Why?
|
| Lewy Body Disease | 1 | 2019 | 97 | 0.040 |
Why?
|
| Amyloid | 1 | 2018 | 57 | 0.040 |
Why?
|
| Amygdala | 1 | 2018 | 42 | 0.040 |
Why?
|
| Serial Learning | 1 | 2018 | 7 | 0.040 |
Why?
|
| Health Status | 1 | 2019 | 219 | 0.040 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 121 | 0.040 |
Why?
|
| Perception | 1 | 2018 | 76 | 0.030 |
Why?
|
| Comoros | 1 | 2017 | 1 | 0.030 |
Why?
|
| Caloric Restriction | 1 | 2017 | 16 | 0.030 |
Why?
|
| Neurofibrillary Tangles | 1 | 2018 | 195 | 0.030 |
Why?
|
| Sphygmomanometers | 1 | 2017 | 2 | 0.030 |
Why?
|
| Autopsy | 1 | 2018 | 343 | 0.030 |
Why?
|
| Massachusetts | 1 | 2017 | 19 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 53 | 0.030 |
Why?
|
| tau Proteins | 1 | 2018 | 235 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2017 | 75 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 193 | 0.030 |
Why?
|
| Czech Republic | 1 | 2014 | 1 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2014 | 30 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2017 | 462 | 0.030 |
Why?
|
| Thalamus | 1 | 2014 | 15 | 0.030 |
Why?
|
| Corpus Striatum | 1 | 2014 | 65 | 0.030 |
Why?
|
| Semantics | 1 | 2014 | 15 | 0.030 |
Why?
|
| Sensation | 1 | 2012 | 12 | 0.020 |
Why?
|
| HIV Long-Term Survivors | 1 | 2010 | 6 | 0.020 |
Why?
|
| HLA-A Antigens | 1 | 2010 | 14 | 0.020 |
Why?
|
| HIV Antigens | 1 | 2010 | 12 | 0.020 |
Why?
|
| HLA-C Antigens | 1 | 2010 | 10 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2010 | 69 | 0.020 |
Why?
|
| Haplotypes | 1 | 2010 | 56 | 0.020 |
Why?
|
| Viral Load | 1 | 2010 | 75 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2011 | 87 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2010 | 83 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2010 | 71 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 270 | 0.020 |
Why?
|
| Logistic Models | 1 | 2010 | 398 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2010 | 116 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2009 | 266 | 0.020 |
Why?
|
| Age Distribution | 1 | 2007 | 87 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2011 | 3551 | 0.010 |
Why?
|